A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Active:	No
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT03400332
Trial Phases:	Phase I Phase II	Protocol IDs:	CA027-002 (primary) NCI-2018-00525 2018-000340-26
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT03400332

Summary

The purpose of this study is to investigate experimental medication BMS-986253 in combination
with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.